Nivolumab Plus Chemotherapy in Gastric Cancer Patients Aged 75 and Older: Real-World Feasibility
This small Japanese retrospective cohort offers hypothesis-generating real-world data on first-line nivolumab-containing chemotherapy with upfront dose reduction in an age group barely represented in pivotal gastric cancer trials.
📅 Journal publication: Aug 3, 2026·Last updated: Nov 3, 2026
Can older gastric cancer patients benefit from nivolumab plus chemotherapy?
Older patients are underrepresented in clinical trials of immune checkpoint inhibitors for gastric cancer. For patients aged ≥ 75 years, median progression-free survival was 5.6 months, similar to younger patients (P = 0.779). Overall survival was 13.3 months (P = 0.852). Findings suggest nivolumab plus chemotherapy is feasible for older patients, but results should be cautiously interpreted due to the small sample size. Nivolumab plus chemotherapy may be a viable option for gastric cancer in patients aged 75 or older.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Yoshimatsu M, Morita S, Ueta Y, Mise M, Inoue N, Ochiai T, Takise S, Fujita J, Muroi H, Nakagawa M, Nakajima M, Yamaguchi S, Kojima K
Citation:Yoshimatsu M, Morita S, Ueta Y, et al. Clinical outcomes of first-line nivolumab plus chemotherapy in patients aged ≥ 75 years with unresectable advanced or recurrent gastric cancer: a retrospective study. World journal of surgical oncology. 2026;24(1). doi:10.1186/s12957-026-04525-x